Arcturus Therapeutics
ARCTAlgoritmens signaler
- ›Starkt 3m-momentum (+118.5%)
- ›Starkt 6m-momentum (+144.1%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (93% årlig)
- ›+184% från 52v-botten
- ›Ökad handelsvolym (+177%)
- ›-35% från 52v-toppen
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsArcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT - marketbeat.com
2026-09-09Arcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT marketbeat.com
marketbeat.comArcturus will take part in five investor events this September - stocktitan.net
2026-08-31Arcturus will take part in five investor events this September stocktitan.net
stocktitan.netARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - Stocktwits
2026-08-22ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ Stocktwits
StocktwitsARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com
2026-08-19ARCT Stock Jumps As Canaccord Backs Vaccine Reset timothysykes.com
timothysykes.comArcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk - simplywall.st
2026-08-08Arcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk simplywall.st
simplywall.stArcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? - finance.yahoo.com
2026-07-03Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? finance.yahoo.com
finance.yahoo.comARCT - Finviz
2026-05-26ARCT Finviz
FinvizArcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha
2026-02-12Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure Seeking Alpha
Seeking AlphaArcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
2025-11-10Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutic
Arcturus TherapeuticsBusiness WireINVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
2025-11-10INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm PR Newswire
Arcturus TherapeuticsPR NewswireArcturus Therapeutics to Attend Upcoming Investor Conferences
2025-11-04Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutic
Arcturus TherapeuticsBusiness WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
2025-10-28Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutic
Arcturus TherapeuticsBusiness WireArcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
2025-10-22Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutic
Arcturus TherapeuticsBusiness WireArcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
2025-08-11Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutic
Arcturus TherapeuticsBusiness WireArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
2025-07-24Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities
Arcturus TherapeuticsBusiness WireArcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
2025-06-30Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities
Arcturus TherapeuticsBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.